SLACS operates by combining spatially-resolved laser activation with advanced sequencing
and proteomics technologies. This innovative approach enables scientists to isolate and analyze
individual cells within their native spatial context, uncovering molecular information across
RNA, DNA, and proteins.
By integrating spatial resolution with multi-omics analysis, SLACS represents a transformative
leap in understanding the molecular landscape of tissues, offering unprecedented opportunities
for breakthroughs in biology and medicine.
SLACS technology represents an advancement over existing advanced sequencing-based analysis
methods and was commercialised for the first time in the industry in 2024.
Meteor Biotech is dedicated to expanding the applications of SLACS while actively developing nextgeneration
technologies.